

Vevzuo™ Denosumab (rDNA Origin)


120 mg/1.7 mL

Solution for Injection Vial
Subcutaneous use

1 single use vial
Each vial contains 120 mg of
denosumab in 1.7 mL
of solution (70 mg/mL)



1.7 mL



CONTROLLED MEDICINE

Composition:

Each vial contains 120 mg denosumab in 1.7 mL of solution (70 mg/mL)

Excipients:


Acetic acid glacial, sodium acetate trihydrate, sodium hydroxide, sorbitol, polysorbate 20, water for injections.

Important:

Do not shake.
Keep medicine out of reach of children.
Jauh dari pada kanak-kanak.
Store in a refrigerator (2°C - 8°C).
Do not freeze. Keep the vial in the outer carton in order to protect from light.
Once removed from the refrigerator, Vevzuo™ may be stored at room temperature (up to 25°C) for up to 30 days in the original container

Indication, dosage and administration:

See enclosed package insert.
This product contains trace element of animal origin from porcine



PC : XXXXXXXXXXXXXXXX
SN : XXXXXXXXXXXX
LOT : XXXXXXXXXXXX
MFG: MM/YYYY
EXP : MM/YYYY



**BATCH CODING AREA
UNVARNISHED ZONE
SERIALISATION**



Vevzuo™ Denosumab (rDNA Origin)

120 mg/1.7 mL

Solution for Injection Vial
Subcutaneous use



1.7 mL

BFXXXXXX/XX



Vevzuo™ Denosumab (rDNA Origin)

120 mg/1.7 mL

Solution for Injection Vial
Subcutaneous use

1 single use vial
Each vial contains 120 mg of
denosumab in 1.7 mL
of solution (70 mg/mL)



1.7 mL



Product Registration Holder:

Biocon Sdn Bhd
No. 1, Jalan Bioteknologi 1, Kawasan
Perindustrian SILC, 79200 Iskandar Puteri,
Johor, Malaysia.

Manufactured and released by:

Biocon Biologics Limited
Block No. B1, B2, B3, Q13 of Q1 and W20 &
Unit S18, 1st Floor, Block B4,
Special Economic Zone, Plot No. 2, 3, 4 & 5,
Phase IV, Bommasandra-Jigani Link Road,
Bommasandra, Bengaluru - 560099, India.

Vevzuo™ has been developed as a similar
biological medicinal product to XGEVA™

This product is subject to medical prescription
Registration no. MALXXXXXXXXXX

BARCODE